Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
← catalyst calendarNCT06268886 · readout in 211 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
310estimated
Sites
176
Countries
Australia, Belgium, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-20 | actual | When the study began enrolling |
| Primary completion | 2027-03-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease, Early Onset
Interventions
- Drug: BMS-986446
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in brain tau deposition as measured by tau positron emission tomography (PET)
measured At week 76
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed